氯沙坦对X综合症大鼠糖脂代谢的影响

目的探讨氯沙坦对x综合症大鼠糖脂代谢的影响.方法采用高果糖饲料饲养两肾一夹SD大鼠4周,诱导建立x综合症模型,实验随机分为对照组;x综合症组;对照组 氯沙坦组;x综合症组 氯沙坦组.每周检测各组尾动脉收缩压,于12周末采血测定各组血糖、血脂、血胰岛素水平,同时计算胰岛素敏感指数.结果x综合症组 氯沙坦组与x综合症组对比,氯沙坦降低了收缩压(P<0.01)、空腹血糖(8.01 mmol/l vs13.81 mmol/lP<0.01)、、甘油三酯(0.88 mmol/l vs 1.53 mmol/lP<0.01)、总胆固醇(0.79 mmol/l vs 1.57mmol/lP<0.01),升高了胰岛素敏感指数(-5.71 vs-6.40P<0.05).结论氯沙坦能降低x综合症大鼠的血压,减轻胰岛素抵抗,纠正糖、脂代谢紊乱.表1,图1,参12.     

The efficacy of maternal age screening for Down's syndrome in Wessex

The uptake of amniocentesis in Wessex for the period 1986–1988 was 36 per cent (2873 of 8004 births), a proportion that has not altered significantly since 1984. There is a large difference in uptake between women in the lower risk age group, 35–36 years, and those in the higher risk group, 37 + years, and very considerable differences in uptake among different districts. The prenatal detection over the 3-year study period for women aged 35 or more, after correction for spontaneous loss of Down's syndrome fetuses between prenatal detection and birth, is 53 per cent, a figure that must be inflated due to our failure to ascertain all liveborn Down's syndrome patients.     

Unusual prenatal presentation of Beckwith–Wiedemann syndrome

When Beckwith–Wiedemann syndrome (BWS) is detected prenatally, it is usually on the basis of macroglossia, exomphalos or enlarged kidneys. We describe a case that presented as gross hepatomegaly and a suspected enlarged pancreas at 20 weeks' gestation, with none of the usual features. Copyright © 2004 John Wiley & Sons, Ltd.     

Screening for fetal Down syndrome with maternal serum hCG and oestriol: A prospective study

We report the preliminary results of a prospective study aimed at evaluating the effectiveness of Down syndrome (DS) screening using second-trimester measurement of maternal serum human chorionic gonadotrophin (hCG) and unconjugated oestriol (uE3) together with maternal age. Reference values for hCG, uE3, and the hCG/uE3 ratio in normal pregnancies were established from more than 3000 normal gestations and found to follow a log-normal statistical distribution. Risk evaluation was made using reference values for affected pregnancies from retrospective studies. Screening of 10 000 women under 38 years resulted in 412 amniocenteses and the prenatal diagosis of six cases of DS, whereas four cases remained undetected until term. In a parallel study, diagnostic amniocentesis was performed in women over 38 years and in women with a previous affected child, and an evaluation of the risk of fetal DS based on serum hCG and uE3 levels was made in all cases. Fourteen cases of DS were detected. Median values for hCG and uE3 in the 24 affected pregnancies were close to the 90th and tenth centiles of the normal reference values, respectively, and thus are in good agreement with the values reported by others in retrospective studies.     

Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses

A prenatal screening programme for Down's syndrome potentially detecting 76 per cent of affected pregnancies in the South Australian general population at an amniocentesis rate of 3.9 per cent was designed following analysis of mid-trimester serum samples from 57 women who carried an affected fetus. This equates to one affected pregnancy being detected for 41 chromosomal analyses performed. For the experimental series, 75.4 per cent of affected pregnancies were detected, while 4.1 per cent of control specimens produced estimated risk odds consistent with further action. A maternal risk odds of birth of a Down's syndrome fetus of 1:420 was taken as the decision value, which is the prevalence of Down's syndrome births to 35-year-old mothers in South Australia. This screening performance was achieved by investigating combinations of serum analytes not previously reported and by refining the calculation of maternal risk odds to include selective weighting of indicator analytes. Combination of the measurements of free α-subunits and β-subunits of chorionic gonadotrophin, α-fetoprotein, unconjugated oestriol, and placental lactogen was found to be most effective in indicating Down's syndrome fetuses. In all combinations of analytes tested, replacing the measurements of free α-subunits and free β-subunits of chorionic gonadotrophin with the measurement of intact chorionic gonadotropin produced a less effective screen.